{"filings":[{"id":442678,"accession_number":"0001193125-26-224022","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2026-05-14T20:10:17+00:00","items":["2.02","9.01"],"status":"ready","headline":"AVITA Medical Q1 revenue $19.3M (+4% YoY); net loss narrows to $10.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $19.3M, up 4% YoY and 10% sequentially, driven by Cohealyx and improved RECELL utilization.","Net loss $10.6M ($0.35 loss per share) vs $13.9M ($0.53 loss) in Q1 2025; operating expenses down 11% to $24.5M.","Gross profit margin 81.7% (vs 84.7%) due to product mix; RECELL-only margin 85.0%.","Reaffirmed FY2026 revenue guidance $80-85M, representing growth of 12-19%.","Appointed Cary Vance as President and CEO; Jan Stern Reed as independent Chair of the Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95275,"accession_number":"0001193125-26-201662","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"AVITA Medical appoints Cary Vance as permanent CEO, Jan Stern Reed as Board Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cary Vance named President and CEO effective April 30, 2026; served as Interim CEO since October 2025.","Jan Stern Reed appointed Chair of the Board; had been Lead Independent Director since October 2025.","Vance receives $702k base salary, 80% bonus target, and $3.354M in equity awards subject to stockholder approval.","Employment agreement: 3-year initial term; severance of 18 months base salary plus COBRA if terminated without cause."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108208,"accession_number":"0001193125-26-048761","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AVITA Medical Q4 revenue down 4% to $17.6M; FY2026 guidance $80-85M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $17.6M (down 4% YoY); gross margin 81.2% vs 87.6%; net loss $11.6M ($0.38/sh) vs $11.6M ($0.44/sh).","Full-year 2025 revenue $71.6M (+11% YoY); net loss $48.6M ($1.74/sh) vs $61.8M ($2.39/sh) in 2024.","Net cash use improved to $5.1M in Q4; cash & marketable securities $18.2M at year-end.","New $60M credit facility with Perceptive Advisors; initial $50M funded, used to repay existing debt.","FY2026 revenue guidance $80-85M (12-19% growth); Cohealyx & PermeaDerm trials fully/significantly enrolled."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":71610000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108207,"accession_number":"0001193125-26-011167","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["1.01","1.02","2.02","2.03","3.02","9.01"],"status":"ready","headline":"AVITA Medical: Q4 rev ~$17.6M, FY2025 $71.6M; new $60M credit facility; FY2026 guidance $80-85M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue ~$17.6M (vs $18.4M Q4 2024); Cohealyx-I fully enrolled, PermeaDerm-I >75% enrolled in Dec 2025.","FY2025 revenue $71.6M, up 11% YoY from $64.3M in 2024, within revised guidance.","FY2026 revenue guidance $80-85M (12-19% growth); TTM revenue covenant $68.5M for Q1 2026, $73M for FY2026.","New $60M credit facility with Perceptive Advisors ($50M funded, $10M option until Q1 2027); SOFR+7.5% (4% floor).","Warrant to purchase 500k shares (additional 150k if $10M drawn) at VWAP-based price; 10-year term; registration rights."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":71610000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108206,"accession_number":"0001193125-26-002418","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"AVITA Medical appoints Joe Woody to board; Lou Panaccio retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joe Woody appointed non-executive director effective Jan 1, 2026; Lou Panaccio retires after 10+ years.","Woody recently served as CEO of Avanos Medical (2017-2024) and CEO of Acelity Holdings.","Annual cash retainer of $92,500; initial equity grant of $210,000 (30% options, 70% RSUs) subject to shareholder approval.","Woody to serve on all Board committees; independence determined by Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124647,"accession_number":"0001193125-25-269535","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"AVITA Medical Q3 revenue falls 13% YoY to $17.1M; lowers FY2025 revenue guidance to $70-74M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss improved to $13.2M ($0.46 loss per share) from $16.2M in Q3 2024; cash use cut to $6.2M.","Full-year 2025 revenue guidance lowered to $70-74M from prior $76-81M, citing MAC reimbursement headwinds.","Sixth amendment to OrbiMed credit agreement adds $500K to principal, resets Q4 2025 revenue covenant to $70M.","RECELL GO received CE Mark under EU MDR; launch to begin in Germany, Italy, and UK.","Operating expenses down 24% YoY to $23.0M as part of cost discipline; cash $23.3M at Sept 30."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":53995000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124646,"accession_number":"0001193125-25-241705","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"AVITA Medical CEO departs, interim CEO appointed; Q3 preliminary revenue ~$17M","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Jim Corbett departed Oct 16, 2025; Chairman Cary Vance appointed Interim CEO effective immediately.","Board member Jan Reed appointed Lead Independent Director; search for permanent CEO commenced.","Preliminary Q3 2025 revenue expected ~$17M; company to provide update on Nov 6 earnings call.","OrbiMed waived Q3 2025 trailing 12-month net revenue covenant; discussions underway to redefine future covenants.","Departure not due to any disagreement with the company on operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141328,"accession_number":"0001762303-25-000026","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"AVITA Medical raises ~$15M via placement of 17.2M CDIs at AU$1.32 each","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 17.2M CHESS Depositary Interests (CDIs) at AU$1.32/CDI; 5 CDIs = 1 common share.","Expected net proceeds of ~$15M (A$22.7M) from Australian institutional/professional investors.","Placement agent fees ~$0.8M in cash and CDIs; transaction expected to close Aug 19, 2025.","Securities exempt from registration under Regulation S; not offered in the U.S."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141327,"accession_number":"0001762303-25-000023","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"AVITA Medical raises US$15M via Australian private placement at A$1.32/CDI","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised ~US$15M (~A$23M) by issuing ~17.2M new CDIs at A$1.32 each (11% discount to last ASX close).","Placement supported by new and existing Australian institutional/professional investors.","Proceeds for working capital and strategic flexibility; expected to fund operations until free cash flow in 2026.","Settlement expected Aug 19, trading on ASX from Aug 20, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141326,"accession_number":"0001762303-25-000012","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"AVITA Medical Q2 revenue $18.4M (+21% YoY); slashes FY2025 revenue guidance to $76M-$81M, delays profitability to 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 commercial revenue $18.4M (+21% YoY); net loss $9.9M vs $15.4M prior year.","FY2025 revenue guidance reduced to $76M-$81M (prior $100M-$106M) due to MAC payment backlog affecting RECELL demand.","Fifth amendment to OrbiMed credit agreement: TTM revenue covenants lowered through Q2 2026; 400,000 common shares issued in lieu of cash fee.","Michael Tarnoff appointed to Board of Directors; adds healthcare leadership experience.","Clinical highlight: RECELL reduces hospital stays 36%; CMS NTAP approved for inpatient trauma wounds."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":36932000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141325,"accession_number":"0000950170-25-104019","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"AVITA Medical appoints Michael Tarnoff to Board; Cary Vance becomes Board Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Michael Tarnoff appointed as non-executive Director, effective August 6, 2025; most recently Chief Physician Executive and CEO at Tufts Medical Center.","Tarnoff receives $70,000 annual cash retainer, initial equity grant of $210,000 (30% options, 70% RSUs); annual grants subject to shareholder approval.","Cary Vance elected Board Chair, succeeding Lou Panaccio after more than 10 years of service; effective August 7, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159140,"accession_number":"0000950170-25-081880","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"AVITA Medical shareholders approve amended incentive plan, increase share reserve by 2.5M","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amended 2020 Omnibus Incentive Plan approved, increasing share reserve by 2.5M to 6.75M shares.","All seven director nominees elected; for-votes ranged from 8.6M to 10.0M across candidates.","Ratified Grant Thornton as independent auditor for FY2025 with 13.4M votes for.","Approved grants to each of six non-executive directors: 10,022 RSUs and 4,295 options each.","Approved grant of options to acquire 520,000 shares to CEO James Corbett."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159139,"accession_number":"0000950170-25-072746","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"AVITA Medical amends bylaws to align with updated Delaware law on shareholder meetings and electronic notice","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Bylaws amended and restated effective May 15, 2025, to reflect recent changes in applicable corporate law.","Updates pertain to conduct of stockholder meetings, electronic notice, and other procedural matters.","Full text of amended bylaws filed as Exhibit 3.1 with the SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159138,"accession_number":"0000950170-25-066911","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AVITA Medical Q1 revenue $18.5M (+67% YoY); reaffirms FY guidance $100-106M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.9M ($0.53/sh) improved from $18.7M loss ($0.73/sh) in Q1 2024.","Gross profit margin 84.7%; RECELL-only margin 86.4%; expects ~$2.5M lower quarterly opex going forward.","Launched RECELL GO mini in Feb; nationwide Cohealyx launch on Apr 1 expanding addressable U.S. market to >$3.5B.","Obtained OrbiMed revenue covenant waiver for Q1; Q2 trailing 12-month covenant set at $78.0M.","Expects to generate free cash flow in H2 2025 and achieve GAAP profitability in Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":18514000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177591,"accession_number":"0000950170-25-040249","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"AVITA Medical to manufacture PermeaDerm; revenue share rises to 60%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["10-year contract manufacturing agreement for PermeaDerm at AVITA's Ventura, CA facility.","Revenue share for AVITA increases to 60% after manufacturing costs (was 50/50).","Stedical eligible for milestone payments tied to AVITA's achievement of sales targets.","Exclusive distribution agreement term extended to ten years from March 17, 2025.","PermeaDerm is FDA-cleared biosynthetic wound matrix; eligible for U.S. reimbursement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177590,"accession_number":"0000950170-25-019862","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"AVITA Medical Q4 revenue $18.4M (+30% YoY), net loss $11.6M; FY2025 guidance $100-106M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 commercial revenue $18.4M (+30% YoY); gross margin 87.6%.","Net loss $11.6M ($0.44 loss per share) vs $7.1M loss in Q4 2023.","FY2025 revenue guidance $100-106M (55-65% growth); expects GAAP profitability in Q4 2025.","Amended OrbiMed credit agreement; adjusted revenue covenants for 2025-2026; issued warrants for 145,180 shares at $0.01/share.","FDA clearances: Cohealyx (Dec 2024) and RECELL GO mini (Dec 2024); full Cohealyx launch by April 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":64251000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177589,"accession_number":"0000950170-25-002907","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AVITA Medical slashes Q4 2024 revenue outlook to ~$18.4M; profitability pushed to Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 commercial revenue expected ~$18.4M (30% YoY growth) vs prior guidance of $22.3-24.3M.","Full-year 2024 revenue now ~$64.3M (29% YoY growth) vs prior $68-70M.","FY 2025 revenue guidance $100-106M (55-65% growth).","Cashflow breakeven and GAAP profitability now expected in Q4 2025, delayed from Q3 2025.","Miss attributed to slower hospital year-end purchasing; new products RECELL GO and Cohealyx remain growth drivers."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":64251000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194297,"accession_number":"0000950170-24-123279","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"AVITA Medical Q3 revenue $19.5M (+44% YoY); amends OrbiMed debt, removes $50M tranches","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Commercial revenue $19.5M, up 44% YoY; gross margin 83.7% vs 84.5%.","Net loss $16.2M ($0.62 loss per share) vs $8.7M loss in prior year quarter.","Amended OrbiMed credit agreement: terminated two $50M tranches, removed Q4 2024 revenue covenant.","Full-year 2024 revenue guidance reaffirmed at $68-70M (37-41% growth); Q4 guidance $22.3-24.3M.","Expects RECELL GO mini FDA approval by Dec 31, 2024; Cohealyx launch Jan 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":45845000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210632,"accession_number":"0000950170-24-093941","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AVITA Medical Q2 commercial revenue record $15.1M (+29%); FY24 guide $68-70M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Commercial revenue $15.1M (+29% YoY); gross margin 86.2% (up 500 bps).","Net loss $15.4M ($0.60 loss per share) vs $10.4M loss ($0.41) in Q2 2023.","RECELL GO PMA approved May 29; RECELL GO mini submitted June 28, FDA decision by Dec 27.","Exclusive distribution deal with Regenity for dermal matrix; 510(k) clearance expected Q4 2024.","Q3 2024 revenue guidance $19-20M (40-48% YoY growth); FY24 guide revised to $68-70M (37-41% growth)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":26299000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210631,"accession_number":"0000950170-24-088572","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"AVITA Medical enters exclusive distribution deal for collagen dermal matrix with Regenity Biosciences","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive 5-year deal for collagen-based dermal matrix; Regenity expects 510(k) clearance in Q4 2024.","AVITA to pay $2M upon 510(k) clearance, up to $3M more by Jan 4, 2026 contingent on clinical results.","Revenue sharing: 50% of avg sales price first 2 years, then 60% in subsequent years.","AVITA to commercialize under its brand in US, EU, Australia, Japan; clinical studies planned for 2025.","CEO Jim Corbett says collaboration strengthens portfolio and may establish new standard of care."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210630,"accession_number":"0000950170-24-079679","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"AVITA Medical appoints Nicole Kelsey as Chief Legal & Compliance Officer; Donna Shiroma retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Donna Shiroma retired as General Counsel effective June 28, 2024, succeeded by Nicole Kelsey.","Shiroma receives $453K severance, $113K prorated bonus, 12 months benefits, equity acceleration.","Shiroma entered a $40K one-month consulting agreement for transition services through July 31.","Kelsey previously Chief Legal Officer at Amyris and General Counsel at Criteo; will lead legal/compliance.","No disagreement cited; retirement was not caused by any disagreements with the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228991,"accession_number":"0000950170-24-069945","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"AVITA Medical shareholders elect directors, approve equity awards at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected: Louis Panaccio, James Corbett, Jeremy Curnock Cook, Suzanne Crowe, Jan Stern Reed, Robert McNamara, Cary Vance.","Stockholders approved RSUs valued at $87,500 and options valued at $37,500 for each non-executive director.","CEO James Corbett granted options to acquire 350,000 shares of common stock, approved by shareholders.","Non-binding advisory vote on named executive officer compensation passed (10,269,125 for, 2,296,661 against).","Ratification of Grant Thornton LLP as independent auditor for FY2024 approved (14,794,234 for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228990,"accession_number":"0000950170-24-066656","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"AVITA Medical receives FDA approval for RECELL GO next-gen skin harvesting device","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved RECELL GO next-gen autologous cell harvesting device for thermal burn wounds and full-thickness skin defects.","Device reduces training burden, improves OR workflow, and controls enzyme incubation for optimal cell yield; launch June 2024.","Clinical benefits: uses less donor skin, reduces pain, speeds closure, cuts procedures, shortens hospital stays for burns <50% TBSA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228989,"accession_number":"0000950170-24-058618","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AVITA Medical Q1 revenue $11.1M (+5.8%), net loss $18.7M; lowers 2024 revenue guidance to lower end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Commercial revenue $11.1M, up 5.8% YoY; gross margin 86.4%.","Net loss $18.7M ($0.73/share) vs $9.2M loss ($0.37) in Q1 2023; operating expenses $26.8M.","Full-year 2024 commercial revenue expected at lower end of $78.5-84.5M range, implying ~57% growth.","Launched PermeaDerm biosynthetic wound matrix in US on March 23, 2024.","RECELL GO FDA decision by May 30, 2024; cashflow breakeven targeted no later than Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":11104000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}